Online Dating

play rummy online for cash_[102009.CОM]

play rummy online for cash_[102009.CОM]Google Chrome enters the address to enter [102009.CОM] Boutique gifts are free of charge. Welcome.EU to work on reducing energy dependence on Russia: EC president.Click the picture to enter the gameClick the picture to enter the game Landmark agreement reached to curb spread of plastic pollutionChinese researchers have developed an mRNA antibody that provided long-term protection against SARS-CoV-2 in animal tests, representing a promising antibody-based therapy for COVID-19 patients.The study, published online in the international journal Cell Research, showed that a neutralizing human monoclonal antibody, called mRNA-HB27-LNP, provided effective protection against SARS-CoV-2 infection in mice for up to 63 days after administration.Researchers from the Academy of Military Medical Sciences and Suzhou Abogen Biosciences Co., Ltd. made the antibody on a well-established mRNA-technology platform.They tested the protective effect of the antibody with different doses and found that all animals that received either 1 mg/kg or 0.2 mg/kg of mRNA-HB27-LNP survived without any clinical symptoms. Treatment with 0.04 mg/kg of the antibody also achieved an 80 percent survival rate, and only minimal or very mild inflammation was observed.The mRNA-HB27-LNP treatment also offered complete protection against the SARS-CoV-2 Beta variant in animal models in the study.In addition, the mRNA technology-based antibody protected 50 percent of mice from SARS-CoV-2 even 63 days after administration, conferring much longer protection compared with traditional protein antibodies.These results with mRNA-HB27-LNP support further clinical development for its potential application in preventing COVID-19, according to the study.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published.